Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma

Inclusion Criteria: * Infants under 6 months * Presenting a hemangioma with the following characteristics: * subcutaneous and / or cutaneous * minimum diameter of 1.5cm on face, 5cm outside face and 3cm if it is ulcerated. * without functional impairment requiring treatment or vital corticosteroid * Consent of both parents (or the person having parental authority in families) * Which at least one parent is a beneficiary of a social security system. Exclusion Criteria: * Indication of treatment with corticosteroids for an indication other than hemangioma * Indication of treatment with beta-blocker for another indication that the hemangioma * Infant presenting cons-indications for the administration of acebutolol or propranolol: * Asthma and chronic obstructive pulmonary disease in their severe forms. * Heart failure controlled by treatment. * Cardiogenic shock * Prinzmetal Angina * Bradycardia (\<80 beats / min at rest the first month \<70/minute from 1 to 6 month). * Raynaud's phenomenon and peripheral arterial disorders in their severe forms. * Pheochromocytoma untreated. * Low blood pressure (blood pressure \<60/30 mmHg before 6 months) * Hypersensitivity to acebutolol or propranolol * History of anaphylactic reaction. * Treatment with amiodarone and / or calcium channel blockers. * Congenital heart disease outside inter auricular communication (CIA) or inter ventricular communication (CIV) insignificant